🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with fibrosis regression on glp-1? Page 5

Has anyone dealt with fibrosis regression on glp-1?

JenMemphis Sat, Apr 26, 2025 at 7:21 PM 46 replies 1,810 viewsPage 5 of 10
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
May 1, 2025 at 11:36 PM#21

From the other side of the consultation, briefly. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

Happy to go further on any of that.

39 12DebRD_ATL, KristenIndy, MarkLI_maint and 36 others
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
May 2, 2025 at 6:50 PM#22
GenomicsKate said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.

Last edited: May 2, 2025 at 9:50 PM
40 13bri_stats, pete_manc_UK, anna.melb_AU and 37 others
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
May 3, 2025 at 2:04 PM#23
GenomicsKate said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Adding the part of the answer the thread has not reached. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.

41 14ingrid_STO, pete_nash, hank_denver and 38 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
May 4, 2025 at 9:19 AM#24

Adding the numbers, since they settle part of this. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

42 15PharmHunterJen, TomTeleRx, DoseLogDan and 39 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
May 5, 2025 at 4:34 AM#25

One thing that is still open after GenomicsKate’s answer:

How would you tell the difference between that and the alternative explanation?

Last edited: May 5, 2025 at 6:34 AM
43 16RickReta_CO, PharmHunterJen, TomTeleRx and 40 others
Reply Quote Save Share Report
13456710

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register